KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) EBITDA: 2016-2024

Historic EBITDA for Moderna (MRNA) over the last 9 years, with Dec 2024 value amounting to -$3.9 billion.

  • Moderna's EBITDA fell 271.43% to -$260.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.5 billion, marking a year-over-year decrease of 28.59%. This contributed to the annual value of -$3.9 billion for FY2024, which is 6.94% up from last year.
  • According to the latest figures from FY2024, Moderna's EBITDA is -$3.9 billion, which was up 6.94% from -$4.2 billion recorded in FY2023.
  • Moderna's EBITDA's 5-year high stood at $13.3 billion during FY2021, with a 5-year trough of -$4.2 billion in FY2023.
  • Its 3-year average for EBITDA is $412.0 million, with a median of -$3.9 billion in 2024.
  • Per our database at Business Quant, Moderna's EBITDA soared by 1,842.60% in 2021 and then slumped by 145.00% in 2023.
  • Moderna's EBITDA (Yearly) stood at -$763.0 million in 2020, then skyrocketed by 1,842.60% to $13.3 billion in 2021, then dropped by 29.15% to $9.4 billion in 2022, then slumped by 145.00% to -$4.2 billion in 2023, then grew by 6.94% to -$3.9 billion in 2024.